Zacks Investment Research upgraded shares of MYOS Corporation (MYOS) from N/A to OUTPERFORM on July 21, 2014, with a target price of $20.00.
We are initiating coverage of MYOS Corporation (NASDAQ: MYOS) with a Buy rating and a $20.00 price target. MYOS is a biotherapeutics and bionutrition company focusing on improving muscle health and function to combat muscle related diseases. The company's commercial division has products on the market, which have been clinically shown to reduce serum myostatin levels. MYOS has differentiated itself from other bionutrition companies based on the solid scientific basis underlying the development of the currently marketed products as well as the current research initiatives underway targeting muscle health. Based on a discounted cash flow analysis, we feel the shares are worth $20.00 and would make a good choice for individuals looking to invest in the emerging area of muscle health.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MYOS Corporation (MYOS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment